The AbsorbaSeal Vascular Closure Device Trial

Peripheral Arterial Disease Clinical Trial

Official title:

Prospective, Multi-center, Non-Randomized Controlled Trial of Vascular Closure Using the AbsorbaSeal 6 French Vascular Closure Device

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03730571
• Other study ID #: CP002CE
• Status: Terminated
• Phase: N/A
• Start date: August 16, 2017
• Est. completion date: April 11, 2019

Study information

• Verified date: September 2021
• Source: ID3 Medical
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study investigates the efficacy and safety of the AbsorbaSeal 6Fr Vascular Closure device (VCD) for the closure of access site of patients requiring percutaneous diagnostic or interventional procedures. An expected total of 50 patients will be enrolled in this study. A total of 12 patients (4 patients per site) will be treated as roll-in phase, prior to enrollment of the first patient. The primary objective of this study is to assess the safety and effectiveness of the AbsorbaSeal 6Fr VCD. Enrollment into this study will include anatomically eligible patients requiring diagnostic and interventional procedures. Following physician training, patients will be enrolled. Efficacy and safety analyses will be based on these patients.Patients will be followed procedurally to discharge, at one month, (follow-up commitment). Secondary objectives are to further characterize adverse events (serious and non-serious), clinical utility measures and health-related quality of life.

Description:

With the increased number of percutaneous interventions being performed in outpatient settings there is a growing need to obtain faster, safer, and more secure hemostasis following these outpatient procedures. CyndRx believes an improved VCD will lead to more widespread use and ultimately improve patient outcomes. The AbsorbaSeal Vascular Closure Device (ABS-6) has been developed to meet this need. The ease of use and automatic deployment of the device will eliminate the learning curve associated with the use of VCDs. The active closure system used in the ABS-6 ensures a secure closure with every deployment. The composition of the seal used is completely bio-absorbable and does not require the use of adjunct materials (i.e. collagen, sutures, staples, etc.) needed in many of the devices currently available.

The First In Man (FIM) trial demonstrated the safety and efficacy of the ABS-6 system in humans (N=20). To further evaluate the safety and efficacy, up to 50 patients will be enrolled in the CP002CE-study.

The primary objective of this study is to assess the safety and effectiveness of the AbsorbaSeal 6Fr VCD. Enrollment into this study will include anatomically eligible patients requiring diagnostic and interventional procedures. Patients will be followed procedurally to discharge, at one month, (follow-up commitment). Secondary objectives are to further characterize adverse events (serious and non-serious), clinical utility measures, and health-related quality of life.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 9
• Est. completion date: April 11, 2019
• Est. primary completion date: April 11, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

• Patient is between 18 and 85 years of age

• Male and Female

• Patient/legal representative provides written informed consent

• Patient is scheduled for a coronary or peripheral diagnostic or interventional procedure

• Patient is able to undergo emergent vascular surgery if a complication related to the VCD necessitates such surgery

• Patient has a 6 french arterial puncture located in the common femoral artery

• Target vessel has a lumen diameter = 5 mm

• Patient is willing and able to complete follow-up

• Catheterization procedure is planned and elective

Exclusion Criteria:

• Prior target artery closure with any closure device or closure with manual compression = 30 days prior to the cardiac or peripheral catheterization procedure

• Patients with a history of significant bleeding or with any known or documented bleeding disorders, such as Thrombocytopenia (with < 100,000 platelet count), Von Willebrand's disease, anemia (Hgb < 10 g/dL, Hct < 30%), thrombasthenia, decreased fibrinogen (< 200 mg/dL), and Factor V deficiency

• Acute ST-elevation myocardial infarction = 48 hours prior to the cardiac or peripheral catheterization procedure

• Patient is ineligible for in-lab catheterization lab introducer sheath removal

• Concurrent participation in another investigational device or drug trial

• Thrombolytic therapy (e.g. streptokinase, urokinase, t-PA) = 24 hours prior to the cardiac or peripheral catheterization procedure

• Evidence of a preexisting hematoma, arteriovenous fistula, or pseudoaneurysm at the access site prior to start of femoral artery closure procedure

• Prior femoral vascular surgery or vascular graft in region of access site or contralateral common femoral artery

• The targeted femoral artery is tortuous or requires a sheath length > 10 cm

• Patient is pregnant or breastfeeding

Related Conditions & MeSH terms

• Peripheral Arterial Disease
• Peripheral Vascular Diseases

Intervention

Device:
• AbsorbaSeal 6Fr Vascular Closure Device
Patients whose access site will be closed with the AbsorbaSeal 6Fr Vascular Closure Device

Locations

Country	Name	City	State
Belgium	O.L.V. Hospital	Aalst
Belgium	Imelda Hospital	Bonheiden
Belgium	A.Z. Sint-Blasius	Dendermonde

Sponsors (2)

Lead Sponsor	Collaborator
ID3 Medical	CyndRx, LLC

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Treatment success	Composite of (1) procedural technical success (successful vascular access and ABS-6 delivery, deployment and catheter removal), (2) absence of vascular complications (arteriovenous fistula, femoral neuropathy, hematoma >6cm, hemorrhage, infection, lymphocele, thrombosis/occlusion/distal emboli/stenosis, vascular injury) (3) absence of major adverse events (all-cause death, cardiac morbidity, neurological complications, renal failure, respiratory complications, secondary intervention for groin complications)	30 days post-index procedure
Secondary	Number of Adverse events	All adverse events will be monitored. A serious adverse event is defined as an event that results in death, is life threatening, requires inpatient hospitalization or that prolongs hospitalization, results in persistent or significant disability/incapacity	30 days post-index procedure
Secondary	Volume of contrast media used during index procedure	Volume of contrast media used (ml)	Intraoperative
Secondary	Fluoroscopy time during index procedure	Fluoroscopy time (min)	Intraoperative
Secondary	Estimated blood loss during index procedure	Estimated blood loss (ml)	Intraoperative
Secondary	Time to hemostasis after index procedure	Time to hemostasis (min)	Intraoperative
Secondary	Total procedure time of index procedure	Total procedure time (min)	Intraoperative
Secondary	Anesthesia time of index procedure	Anesthesia time (min)	Intraoperative
Secondary	Total time of initial hospitalization stay	Total time of initial hospitalization stay (h:min)	Up to 1 month post-index procedure
Secondary	Analgesic usage after index-procedure	Arterial access site pain-related analgesic usage after index procedure until patient discharge	1-day post-index procedure
Secondary	Pain Evaluation	Self-reported groin pain scale (0 (no pain) - 10 (excessive pain))	1-day post-index procedure and 1 month follow-up